Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) recently released its financial results for the third quarter ending September 30, 2024, along with a comprehensive business update. The company, known for developing a novel class of antibiotics to combat challenging bacterial infections, highlighted several key achievements during this period. In July 2024, notable outcomes from the ibezapolstat (IBZ) […]

MALVERN, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) — via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced financial results for the third quarter ended September 30, 2024, and provided a business update.